{
    "@context": "http://schema.org",
    "@type": "Drug",
    "@id": "https://kisunla.lilly.com/",
    "url": "https://kisunla.lilly.com/",
    "name": "Kisunla®",
    "manufacturer": {
      "@type": "Organization",
      "name": "Eli Lilly and Company"
    },
    "nonProprietaryName": "donanemab-azbt",
    "isProprietary": true,
    "administrationRoute": "Intravenous Infusion (IV)",
    "prescriptionStatus": "PrescriptionOnly",
    "labelDetails": "https://uspl.lilly.com/kisunla/kisunla.html#mg",
    "doseSchedule": {
      "@type": "DoseSchedule",
      "doseValue": "700 mg",
      "frequency": "every four weeks for the first three doses, followed by 1400 mg every four weeks"
    },
    "dosageForm": "Injection/Infusion",
    "drugUnit": "Injection: 350mg/20mL (17.5 mg/mL) in a single-dose vial.",
    "mechanismOfAction": "Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. Donanemab-azbt reduces amyloid beta plaques, as evaluated in Study 1.",
    "prescribingInfo": "https://uspl.lilly.com/kisunla/kisunla.html#pi",
    "description": "KISUNLA is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.",
    "warning": "Kisunla can cause Amyloid-Related Imaging Abnormalities or ARIA. This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal. ARIA is most commonly seen as temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the brain and infrequently, larger areas of bleeding in the brain can occur.",
    "relevantSpecialty": [
      {
        "@type": "MedicalCondition",
        "name": "Kisunla is an FDA-approved treatment for early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease."
      }
    ],
    "recognizingAuthority": [
      {
        "@type": "Organization",
        "name": "FDA",
        "url": "https://www.fda.gov/"
      }
    ],
      "aggregateRating": {
          "@type": "AggregateRating",
          "ratingValue": 4.7,
          "reviewCount": 5
        }
    }